Affiliation:
1. Charité - Universitätsmedizin Berlin
2. Charité Universitätsmedizin Berlin, Charité Campus Mitte
3. Central Institute of Mental Health, Heidelberg University
4. Charité – Universitätsmedizin Berlin
Abstract
Abstract
Background
Distressing nightmares are a core symptom of posttraumatic stress disorder (PTSD) and contribute to psychiatric comorbidity, impaired physical health and decreased social functioning. No specific pharmacological treatment for PTSD-related nightmares is yet approved. Preliminary clinical data indicate that cannabinoid agonists can improve nightmares and overall PTSD symptoms in patients with PTSD. The primary objective of the study is to examine the efficacy of oral dronabinol (BX-1) versus placebo in reducing nightmares in patients with PTSD. The secondary objectives of the study are to examine the efficacy of oral BX-1 in reducing other PTSD symptoms.
Methods
The study is designed as a multi-centric, double-blind, randomized (1:1), placebo-controlled, parallel group interventional trial. Eligible patients will be randomized to BX-1 or placebo, receiving a once-daily oral dose before bedtime for 10 weeks. Primary efficacy endpoint is the Clinician-Administered PTSD Scale (CAPS-IV) B2 score for the last week, measuring frequency and intensity of nightmares. Secondary efficacy endpoints are other disorder-specific symptoms in patients with PTSD. Further, tolerability and safety of dronabinol will be assessed.
Discussion
This randomized controlled trial will provide evidence whether treating patients with PTSD and nightmares with dronabinol is safe and efficacious.
Trial registration
NCT04448808, EudraCT 2019-002211-25
Publisher
Research Square Platform LLC
Reference20 articles.
1. Randomized controlled trials of psychological and pharmacological treatments for nightmares: a meta-analysis;Augedal AW;Sleep Med Rev,2013
2. Use and effects of cannabinoids in military veterans with posttraumatic stress disorder;Betthauser K;Am J Health Syst Pharm,2015
3. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM. (1995). The development of a Clinician-Administered PTSD Scale. J Trauma Stress, 8(1), 75–90. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/7712061
4. The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial;Bonn-Miller MO;PLoS ONE,2021
5. Posttraumatic stress symptom severity predicts marijuana use coping motives among traumatic event-exposed marijuana users;Bonn-Miller MO;J Trauma Stress,2007